VIDEO: Many new developments in vasculitis treatment

Editor's note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Well, we are very excited that we have multiple development in the study of treatment of vasculitis, and this is all because we come together as a community of different investigators and put all the efforts together, so now we've seen in the past five, 10 years, and a little bit more, that we have a group of investigators that, although this is a rare disease, we are able to look at this into a more inclusive matter, and it helped us have a lot of patients into one study. So, for example, you know, just from the American College of Rheumatology meeting that we just had in November, we have had multiple studies.

They were presented and some of them took the plenary session. We learned that abatacept did not reduce the risk of relapse in ANCA-associated vasculitis. There was a lot of efforts in the past years of looking and investigating EGPA, eosinophilic granulomatosis with polyangiitis, and the MANTRA trial was presented in the ACR meeting, which showed that benralizumab is non-inferior to mepolizumab in both airway and non-airway manifestation in EGPA. We also was a major study that was also presented in, it was a SELECT-GCA trial, and this was a trial in giant cell arteritis, and which showed that upadacitinib in a dose of 15 milligram was more efficacious in reducing glucocorticoid in GCA.

And we kept seeing multiple post-hoc studies after the advocate trial that was presented a few years ago, and now we have seen multiple analysis of post-hoc analysis that shows that avacopan is efficacious in other than non-renal involvement such as ENT involvement, general symptoms, nervous system involvement, skin, eyes, and other involvement as well. So, I can keep going and going, but these were the highlight of the major studies that were presented at the American College of Rheumatology recently.